newsfilter
← Latest News
ClinicalTrials.gov·

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study - NCT05692999

Overall survival, Progression-free survival, Duration of response between both treatment arms., (and 9 more...)